Cardiovascular Research (2015) 105, 372–382
doi:10.1093/cvr/cvv007
Reduction of mouse atherosclerosis by urokinase
inhibition or with a limited-spectrum matrix
metalloproteinase inhibitor
Jie Hong Hu 1, Phanith Touch 1, Jingwan Zhang 1, Hao Wei 1, Shihui Liu 2,
Ida K. Lund 3, Gunilla Høyer-Hansen 3, and David A. Dichek 1*
1
Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA; 2National Institute of Allergy and Infectious Diseases, National Institutes of Health,
Bethesda, MD, USA; and 3The Finsen Laboratory, Copenhagen University Hospital and Biotech Research & Innovation Centre, Copenhagen University, Copenhagen, Denmark
Received 17 July 2014; revised 22 December 2014; accepted 6 January 2015; online publish-ahead-of-print 23 January 2015
Time for primary review: 29 days
Aims
Elevated activity of urokinase plasminogen activator (uPA) and MMPs in human arteries is associated with accelerated
atherosclerosis, aneurysms, and plaque rupture. We used Apoe-null mice with macrophage-specific uPA overexpression
(SR-uPA mice; a well-characterized model of protease-accelerated atherosclerosis) to investigate whether systemic
inhibition of proteolytic activity of uPA or a subset of MMPs can reduce protease-induced atherosclerosis and aortic
dilation.
.....................................................................................................................................................................................
Methods
SR-uPA mice were fed a high-fat diet for 10 weeks and treated either with an antibody inhibiting mouse uPA (mU1) or a
and results
control antibody. mU1-treated mice were also compared with PBS-treated non-uPA-overexpressing Apoe-null mice.
Other SR-uPA mice were treated with one of three doses of a limited-spectrum synthetic MMP inhibitor (XL784) or
vehicle. mU1 reduced aortic root intimal lesion area (20%; P ¼ 0.05) and aortic root circumference (12%; P ¼ 0.01).
All XL784 doses reduced aortic root intimal lesion area (22–29%) and oil-red-O-positive lesion area (36 –42%;
P , 0.05 for all doses and both end points), with trends towards reduced aortic root circumference (6–10%).
Neither mU1 nor XL784 significantly altered percent aortic surface lesion coverage. Several lines of evidence identified
MMP-13 as a mediator of uPA-induced aortic MMP activity.
.....................................................................................................................................................................................
Conclusions
Pharmacological inhibition of either uPA or selected MMPs decreased atherosclerosis in SR-uPA mice. uPA inhibition
decreased aortic dilation. Differential effects of both agents on aortic root vs. distal aortic atherosclerosis suggest prevention of atherosclerosis progression vs. initiation. Systemic inhibition of uPA or a subset of MMPs shows promise
for treating atherosclerosis.
----------------------------------------------------------------------------------------------------------------------------------------------------------Keywords
Atherosclerosis † Urokinase † Matrix metalloproteinases † Protease inhibition † Mouse models
1. Introduction
Extracellular proteases [including matrix metalloproteinases (MMPs),
serine proteases, and cysteine proteases] are expressed in diseased arteries and play critical roles in several biological processes that contribute to vascular disease: cell migration, extracellular matrix metabolism,
vasoconstriction, vascular wall permeability, thrombosis, apoptosis, and
cell proliferation.1 – 3 These processes contribute—in turn—to atherosclerotic lesion growth, aneurysm formation, and plaque rupture.
Proteases are among the most common drug targets.4 However, considering the diverse pathways through which proteases contribute to
vascular disease—and the large number of proteases that appear to accelerate vascular disease1—protease inhibition appears underused in
cardiovascular therapeutics.
Urokinase-type plasminogen activator (uPA)5,6 and certain MMPs7
are among the proteases that contribute to atherosclerosis and its complications. Accordingly, the primary goal of the present study was to
begin to investigate the potential of two novel protease inhibitors—an
antibody that inhibits uPA5 and a small-molecule selective MMP inhibitor
(XL784)8—to prevent atherosclerosis. To begin to test these inhibitors,
we administered them to atherosclerosis-prone (Apoe 2/2 ) mice that
have macrophage-specific overexpression of uPA.5 These ‘SR-uPA’
* Corresponding author. Tel: +1 206 685 6959; fax: +1 206 221 6346. Email: [email protected]
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2015. For permissions please email: [email protected].
373
Protease inhibition to treat atherosclerosis
mice have accelerated atherosclerosis and aortic dilation that are
mediated by activation of the uPA substrate plasminogen,9 itself a broadspectrum serine protease.10 SR-uPA mice also have elevated aortic MMP
activity and develop histologic correlates of atherosclerotic plaque instability, including intraplaque haemorrhage and fibrous cap disruption.11 Because—as is likely the case with humans6,12—SR-uPA mice
have protease-driven atherosclerosis, aortic dilation, and plaque
rupture, they are an appropriate experimental setting for beginning to
test whether pharmacological inhibition of uPA or select MMP activities
can retard or prevent atherosclerosis. If ineffective in SR-uPA mice, these
inhibitors would be unlikely to prevent atherosclerosis in other mouse
models or humans. If effective, further preclinical testing (for example in
atherosclerosis-prone mice that do not overexpress proteases or in
older SR-uPA mice susceptible to plaque rupture)11 as well as clinical
testing of these inhibitors would be warranted.
Here we report that both antibody-based uPA inhibition13 and selective MMP inhibition with XL7848 decrease atherosclerosis in SR-uPA
mice. Antibody-based uPA inhibition decreases aortic root dilation.
These results encourage further development and testing of these or
other uPA and MMP inhibitors as human cardiovascular therapeutics.
Our data also tentatively identify MMP-13 as a downstream mediator
of uPA-induced vascular pathology.
2. Methods
2.1 Animals
All mice were Apoe 2/2 and were progeny of at least 10 generations of
C57BL/6 backcrosses. Apoe 2/2 mice with macrophage-specific overexpression of urokinase (‘SR-uPA’ mice, hemizygous for a transgene that includes
the murine uPA gene driven by the human scavenger receptor promoter)
were generated in our laboratory.5 SR-uPA mice were bred with nontransgenic (SR-uPA0/0) Apoe 2/2 mice to yield SR-uPA and non-transgenic littermate controls. Mice were housed in a specific-pathogen-free facility and
genotyped by PCR for the SR-uPA allele.14 Chow-fed mice of both genders
were used to test susceptibility to a uPA-activated toxin and to investigate
protective effects of an antibody to uPA. Fat-fed female mice were used
for atherosclerosis studies. Fat-fed male mice were used for a study comparing MMP-13 activity in medium conditioned by aortas of SR-uPA and nontransgenic mice. All animal protocols were approved by the University of
Washington Office of Animal Welfare (animal protocol #3339-01) and
were performed according to NIH guidelines.
2.2 Susceptibility to a uPA-activated toxin
Both SR-uPA and non-transgenic mice were injected intraperitoneally with
PrAg-U2 [a mutated version of anthrax protective antigen (PrAg), in which
the furin cleavage site of PrAg is replaced by a uPA substrate sequence]
and FP59 (a recombinant effector protein that kills cells in a PrAg-dependent
manner).15,16 When combined, PrAg-U2 and FP59 comprise a toxin that
lacks the broad cellular toxicity of native PrAg and instead has a highly specific
toxicity for cells with surface uPA activity. After injection, mice were monitored closely for signs of toxicity including weight loss, inactivity, and inappetence and were euthanized by carbon dioxide (CO2) inhalation when
toxicity appeared. Toxicity was also considered present when an injected
mouse was found dead. To identify a highly toxic dose of PrAg-U2/FP59 in
C57BL/6 Apoe 2/2 mice, we first used a fixed dose of FP59 (10 mg per
mouse; 0.5 mg/kg body weight) along with escalating doses of PrAg-U2
(0.4– 2.4 mg/kg body weight). Because we found low toxicity with this
regimen we injected higher doses: 3.2 mg/kg FP59 and 9.6 mg/kg PrAg-U2.
Our goal was to achieve a high level of toxicity, thereby permitting investigation of whether injection of the murine mAb mU1 (which inhibits mouse uPA
activity)13 would block PrAg-U2/FP59 toxicity in SR-uPA (i.e.
uPA-overexpressing) as well as non-transgenic mice. mU1 was generated
by immunizing uPA knockout mice with recombinant mouse pro-uPA and
subsequent hybridoma generation.13,17 Use of a murine mAb in these
experiments eliminates concerns about immune responses to antibody
therapy and ensures specificity of the antibody target. To determine
whether mU1 inhibits PrAg-U2/FP59 toxicity, we first injected mice intraperitoneally with either mU1, an isotype-control mAb directed at trinitrophenol (TNP;13 both at 60 mg/kg), or PBS (200 mL). Preparations of both
antibodies were endotoxin-free. These same injections were repeated the
next day. Immediately after this second injection of antibody or PBS, mice
were injected with 9.6 mg/kg PrAg-U2 and 3.2 mg/kg FP59. Mice were
observed twice per day for 7 days for signs of toxicity.
2.3 Atherosclerosis studies
Mice were fed a high-fat diet (21% fat, 0.15% cholesterol by weight; HarlanTeklad, Kent, WA #TD.88137) beginning at 5 – 6 weeks of age and continuing
for 10 weeks. To test for therapeutic effects of mU1 (the ‘mU1 study’; Supplementary material online, Figure S1), mice were injected with a loading dose
of antibody (mU1 or anti-TNP; 100 mg/kg) or a similar volume of PBS at the
time the high-fat diet was begun. The primary hypothesis tested in the mU1
study was that injection of mU1 would reduce atherosclerosis and aortic
dilation compared with the anti-TNP control group. A group of PBS-injected
non-transgenic mice was added while this experiment was in progress. We
added this third group of mice to test a secondary hypothesis: that mU1
treatment would completely eliminate the effect of the SR-uPA transgene
on atherosclerosis and aortic dilation. The half-life of mU1 is 3 days and
therefore injections of antibody (50 mg/kg) or a similar volume of PBS
were repeated twice weekly for the study duration. To test for therapeutic
effects of the MMP inhibitor XL784,8 (the ‘XL784 study’; Supplementary material online, Figure S1) mice were gavaged daily with one of the three doses of
XL784 (125, 250, or 500 mg/kg; prepared freshly in vehicle) or with vehicle
alone [by volume: 12.5% Cremophorw EL (Sigma-Aldrich Corp, St Louis,
MO, USA), 12.5% ethanol; and 75% Hank’s Balanced Salt Solution]. We
chose this range of XL784 doses based on unpublished data (now published)18 showing that 500 mg/kg/day of XL784 was highly effective in limiting
experimental aneurysm formation. We also tested whether lower doses
might be similarly effective. After 10 weeks on high-fat diet, mice were
deeply anaesthetized by IP injection of ketamine (225 mg/kg) and xylazine
(23 mg/kg), their blood and plasma collected, then exsanguinated by saline
perfusion. Aortas were removed, trimmed, rinsed, and incubated overnight
in M199 (GIBCO, Carlsbad, CA, USA) at 378C with 5% CO2. Culture
medium conditioned by the explanted aortas (CM) was then stored at
2808C and the aortas were fixed by incubation in formalin. Hearts (with
attached aortic roots) were placed in fixative [10% phosphate-buffered formalin pH 7.4, containing 220 mM sucrose, 2 mM EDTA, 0.02 mM butylated
hydroxytoluene (Sigma)] for at least 48 h. The hearts were then divided
transversely. The base and attached aortic root were embedded in
optimal cutting temperature medium and frozen.5
2.4 Measurement of plasma total and
HDL-cholesterol, triglycerides, blood counts,
and aortic MMP activity
Total plasma cholesterol and triglycerides were measured with blood
obtained from the retro-orbital plexus (Spectrum cholesterol assay,
Abbott Diagnostics, Abbott Park, IL; L-Type TG M, Wako Diagnostics,
Mountain View, CA, USA). HDL-cholesterol in the same samples was measured (Sekisui Diagnostics, Lexington, MA, USA) after PEG precipitation of
apoB-containing lipoproteins, and non-HDL-cholesterol was calculated.
Complete blood counts (blood collected from the same location) were performed by an outside laboratory (Phoenix Central Laboratory, Mukilteo,
WA, USA). Total MMP activity in aortic CM was measured with the Omni
MMP substrate (Enzo Life Sciences, Farmingdale, NY, USA).11 Activities of
MMP-8 and MMP-13 in aortic CM were measured using fluorogenic
374
substrates [MMP-8 substrate: DNP-Pro-Leu-Ala-Tyr-Trp-Ala-Arg, (Sigma);
MMP13 substrate: MCA-Pro-Cha-Gly-Nva-His-Ala-Dpa-NH2; (EMD Millipore, Billerica, MA, USA)].19 The MMP-13 substrate is also cleaved by
MMP-8. However, according to the manufacturer, MMP-8 cleaves this substrate at lower efficiency. A separate cohort of male mice, used to
measure MMP-13 activity in aortic CM, was fed the high-fat diet for 15
weeks beginning at age 6 – 8 weeks.
2.5 Measurement of MMP-13 mRNA
and protein
MMP-13 mRNA was measured by quantitative RT-PCR using RNA
extracted from aortas of non-transgenic Apoe2/2 recipients of either
SR-uPA Apoe2/2 or non-transgenic Apoe2/2 bone marrow. These aortic
mRNA samples were available from past experiments.11,14 PCR primers
for MMP-13 were: 5′ -AAAGATTATCCCCGCCTCAT-3′ and 5′ -TGGGC
CCATTGAAAAAGTAG-3′ .20 MMP-13 mRNA levels were normalized to
GAPDH mRNA measured in the same samples.21 MMP-13 protein was
detected by western blot analysis of aortic CM obtained from mice in the
present study. For each sample, 24 mL of CM were separated by SDS –
PAGE and transferred to PVDF membranes.14 MMP-13 was detected with
a rabbit antibody to mouse MMP-13 (1:500, Santa Cruz Antibodies, Santa
Cruz,CA; #SC-30073) and peroxidase-conjugated anti-rabbit IgG (1:2,000;
Bio-Rad, Hercules, CA, USA; #170-6515). To control for protein loading,
membranes were stripped and re-probed with a mouse mAb to GAPDH
(1:2,000; Sigma #G9545). Recombinant human MMP-13 protein (cat
#RP-77530; 200 mg/mL; Thermo Scientific, Fife, WA, USA) was activated
by treatment with amino-phenyl mercuric acetate (APMA) (2.5 mM;
Sigma) in TCC buffer (50 mM Tris – HCl, 1 mM CaCl2, 0.05% Triton
X-100, pH 7.5) at 378C for 1 h at a 4:1 volume ratio (MMP-13:APMA). Activated MMP-13 cleaved both the OMNI-MMP and MMP-13 substrates, with
both activities inhibited by EDTA (data not shown). Fragments of APMAtreated MMP-13 were analysed by SDS – PAGE under reducing conditions,
with silver staining of the gels.
2.6 Tissue processing and morphometry
We measured aortic surface atherosclerosis on full-length aortas of mice in
the mU1 study and on the thoracic aortas of mice in the XL784 study. The
reason for this was that we encountered unanticipated abnormalities in
the abdominal aortas of mice in the XL784 study and decided to process
many of these abdominal aortas into paraffin. These abnormalities were
associated with exposure to the Cremaphor vehicle, not XL784, and are
not reported here. For surface atherosclerosis quantitation, aortas were
pinned on a wax board and stained with Sudan IV. Total aortic surface
area and Sudan IV-positive area were measured, and percentage surface
Sudan IV-positivity calculated.5 The number of surface lesions on each
aorta was also counted.
Aortic roots of mice in both studies were sectioned (8-mm thickness).5
Sections taken at 56-mm steps were stained with H&E, oil-red-O, and
Mac-2.5,21 For each stain, a total of 5– 7 step sections per aortic root were
analysed. Aortic root intimal area, internal elastic lamina (IEL) circumference,
oil-red-O-positive intimal area, and Mac-2-positive intimal area were measured on digital images of the sections (Image-Pro Plus; Media Cybernetics,
Rockville, MD, USA) by an observer blinded to treatment, using colour
thresholding for the oil-red-O and Mac-2 stains.11 The percentages of
intimal lesions staining with oil-red-O and Mac-2 were calculated using
total intimal area measured on an adjacent H&E-stained section as the
denominator.
2.7 Statistical analysis
Data are mean + SD or median (25– 75% range). Groups were compared
with the unpaired t-test or with the Mann– Whitney rank-sum test if data
were non-normally distributed or group variances were unequal. These
tests were used when comparisons between two groups were
J.H. Hu et al.
contemplated a priori, as in the experiments that primarily compare mU1
with anti-TNP treatment and secondarily compare mU1-treated SR-uPA
mice to PBS-treated non-transgenic mice. This approach does not correct
for multiple comparisons; however, we believe that it is justified by our experimental design, which prioritizes the first comparison as the primary end
point. In experiments testing multiple doses of XL784, we used one-way
ANOVA (followed by Dunnett’s method for post hoc correction for multiple
comparisons) to test whether each of the treatment groups differed significantly from the control group. When conditions of normality and equal variance were not met, we used Kruskal– Wallis ANOVA, also with post hoc
correction. To identify trends that might guide future research, we also performed t-tests between the XL784-treated groups and the control group.
Results of these t-tests are not corrected post hoc for multiple comparisons
and accordingly should be viewed as hypothesis-generating. Toxicity-free
survival curves were generated with the Kaplan– Meier method and compared with the log-rank test. Categorical data (e.g. presence or absence of
PrAg-U2/FP59 toxicity) were analysed by chi square or Fisher exact test.
Correlations were analysed using the Pearson Product Moment test. All
tests were carried out with the SigmaStat program (Systat Software,
Chicago, IL, USA).
3. Results
3.1 Activity of a uPA-Activated toxin
in SR-uPA mice
Identification of a highly toxic dose of the uPA-activated toxin
PrAg-U2/FP5915 was necessary in order to enable us to test whether
the uPA-inhibitory antibody mU113 could inhibit uPA activity in
uPA-overexpressing SR-uPA Apoe 2/2 mice. Experiments with low
PrAg-U2/FP59 doses (used in published studies)16,22 revealed equivalent
but modest toxicity in both SR-uPA and non-transgenic mice (data not
shown). A larger experiment with a higher dose of PrAg-U2 (2.4 mg/
kg with 0.5 mg/kg FP59) also showed equivalent—but still submaximal—toxicity (10 of 20 SR-uPA mice and 14 of 20 non-transgenic
mice; P ¼ 0.3). We therefore increased the doses of both agents (to
9.6 mg/kg PrAg-U2 and 3.2 mg/kg FP59), achieving 91% toxicity (10 of
11 mice). We anticipated that this highly toxic dose of PrAg-U2/FP59
would allow detection of protective effects of mU1 using a relatively
small number of mice.
3.2 MU1 delays toxicity of a uPA-activated
toxin in SR-uPA mice
We next tested whether mU1 could protect SR-uPA mice from uPAdependent PrAg-U2/FP59 toxicity. Non-transgenic mice (which
express far lower levels of uPA than SR-uPA mice)5,14 were included
as a positive control, potentially useful in the event mU1 was ineffective
in SR-uPA mice. To our knowledge, susceptibility of mice to PrAg-U2/
FP59 is the most sensitive and specific measure of in vivo uPA activity.15,16
Therefore, protection from PrAg-U2/FP59 toxicity would be the best indication that mU1 decreases in vivo uPA activity in SR-uPA mice. Only 3 of
22 (14%) of PrAg-U2/FP59-injected mice that received either anti-TNP
or PBS were still healthy by the end of day 2. These included 2 of 14 (14%)
SR-uPA mice and 1 of 8 (12%) non-transgenic mice (see Supplementary
material online, Table S1). In contrast, mU1 delayed toxicity beyond day 2
in 6 of 6 (100%) PrAg-U2/FP59-injected SR-uPA mice and 3 of 4 (75%)
PrAg-U2/FP59-injected non-transgenic mice (P ¼ 0.4 for comparison of
SR-uPA and non-transgenic mice, indicating equivalent efficacy of mU1
in both lines). Combining the data from SR-uPA and non-transgenic
mice, mU1 significantly extended survival of PrAg-U2/FP59-injected
375
Protease inhibition to treat atherosclerosis
mice (see Supplementary material online, Figure S2; P ¼ 0.02). Therefore, mU1 is equally (although incompletely) protective in both
uPA-overexpressing SR-uPA and non-transgenic mice. Because mU1
significantly decreases in vivo uPA activity (required for PrAg-U2/FP59
toxicity)15 in Apoe 2/2 mice, mU1 is a useful reagent for testing the hypothesis that in vivo pharmacological suppression of uPA activity in
SR-uPA Apoe 2/2 mice will prevent uPA-induced atherosclerosis and
its complications.
3.3 MU1 partially prevents accelerated
atherosclerosis and aortic dilation in
SR-uPA mice
Compared with mice treated with the control anti-TNP antibody,
SR-uPA mice treated with mU1 had less aortic root intimal lesion area
(20% decrease; P ¼ 0.05; Figure 1A, C and D) and smaller aortic root circumferences (12% decrease; P ¼ 0.01; Figure 1B– D). mU1 decreased
total intimal macrophage-positive and ORO-positive areas by similar
amounts (20–30%); however, these differences were not statistically
significant (P ¼ 0.3 and P ¼ 0.4, respectively; Table 1). Accordingly,
neither the percentage of intimal lesion area occupied by macrophages
nor the percentage occupied by lipid was decreased by mU1 (P ¼ 1.0
and 0.4, respectively; Table 1). Analysis of Sudan IV-stained, pinned
aortas revealed non-significant trends towards less total aortic
surface area (5% decrease) and lower percent coverage of the aortic
lumen surface with lesions (20% decrease) in mU1-treated vs.
anti-TNP-treated mice (P ¼ 0.1 for both; Table 1). The number of individual lesions on pinned aortic surfaces did not differ between the two
groups (P ¼ 0.3; Table 1).
To determine whether treatment with mU1 eliminated the contribution of uPA overexpression to murine atherosclerosis, we compared
atherosclerosis and aortic root circumference between mU1-treated
SR-uPA mice and PBS-treated non-transgenic mice. PBS-treated nontransgenic mice had significantly smaller aortic root lesion area and
aortic root circumference than mU1-treated SR-uPA mice (30 and
15% smaller, respectively; P ¼ 0.01 for both; Figure 1A, B, and E).
PBS-treated non-transgenic mice also had significantly less aortic root
lesion oil red O area and tended to have less aortic root lesion macrophage area than mU1-treated SR-uPA mice (30% decrease for both;
P ¼ 0.03 and 0.07, respectively; Table 1).
3.4 XL784 significantly reduces
atherosclerosis in SR-uPA mice
Treatment with all three doses of XL784 significantly reduced aortic
root intimal lesion area (20–30%; P , 0.05 for all doses; Figure 2A). All
three doses of XL784 also significantly reduced total aortic root
lesion oil red O-positive area (36–42%; P , 0.05 for all three doses;
Figure 2B). All XL784 doses also nominally reduced total aortic root
lesion macrophage-positive area (15 –33%). This result was of only borderline statistical significance (P ¼ 0.1 by one-way ANOVA); however,
the highest XL784 dose had a significant effect by t-test (P ¼ 0.02;
Figure 2C). Neither the percentage of lesion oil red O-positivity nor
the percentage of macrophage positivity in aortic root lesions were significantly affected by XL784 (P ≥ 0.2; Table 2). All doses of XL784 also
yielded non-significant trends towards reduced aortic root circumference (6–10% for all three; P ¼ 0.17 by one-way ANOVA; by t-test the
lowest dose reduced circumference significantly; P , 0.05; Figure 2D).
Figure 1 Antibody-mediated inhibition of uPA decreases aortic root atherosclerosis and aortic root dilation in uPA-overexpressing (SR-uPA) mice.
SR-uPA mice were treated for 10 weeks with either the control anti-TNP antibody (n ¼ 9) or the uPA-inhibitory antibody mU1 (n ¼ 10). Littermate nontransgenic (Ntg) mice were treated with PBS (n ¼ 11), also for 10 weeks. (A) Mean intimal area of aortic root lesions. (B) The circumference of the aortic
root at the level of the internal elastic lamina (IEL). Data points are individual mice and bars are group means. (C– E) Aortic root lesions in
uPA-overexpressing (SR-uPA) mice treated with (C ) the control anti-TNP antibody or (D) the uPA-inhibitory antibody mU1, and (E) in non-transgenic
mice treated with PBS. Haematoxylin and eosin stain; size bar (C) ¼ 500 mm. (C– E) are representative images of 9 – 11 aortas per group.
376
J.H. Hu et al.
Table 1 Atherosclerosis in mU1- and anti-TNP-treated SR-uPA mice
SR-uPA+/0 1
a-TNP (n)
SR-uPA+/0 1
mU1 (n)
Aortic root Mac-2 area (mm2 × 105)
1.50 + 0.81 (9)
1.20 + 0.58 (10)
0.3
0.79 + 0.23 (11)
0.07
Aortic root Mac-2 area (% of intimal area)
Aortic root oil red O area (mm2 × 105)
16 + 7.8 (9)
1.3 + 0.30 (9)
17 + 9.0 (10)
1.1 + 0.42 (10)
1.0
0.4
16 + 5.0 (11)
0.77 + 0.22 (11)
0.8
0.03
Aortic root oil red O area (% of intimal area)
15 + 3.9 (9)
17 + 6.6 (10)
0.4
16 + 3.1 (11)
0.5
Total aortic lumen surface area (mm2)
Sudanophilic lesions (% of total aortic lumen surface area)
59 (56–60) (9)
2.2 (1.8– 3.0) (9)
56 (53–58) (10)
1.7 (1.5– 2.0) (10)
0.1
0.1
53 (51– 55) (11)
0.45 (0.27– 2.1) (11)
0.2
0.3
P (a-TNP vs
mU1)
SR-uPA0/0 1
PBS (n)
P (mU1 vs.
SR-uPA0/0)
.......................................................................................................................................................................................
Number of lesions on pinned aortic surface
14 (12–17) (9)
13 (11–16) (10)
0.3
11 (8 –14) (11)
0.2
Peripheral blood monocytes (per mL)
Peripheral blood monocytes (% total leukocytes)
140 + 100 (5)
3.0 (2.0– 4.0) (5)
260 + 160 (5)
3.0 (2.5– 7.0) (5)
0.2
0.7
180 + 160 (5)
2.0 (2.0–4.5) (5)
0.5
0.6
Plasma cholesterol (mg/dL)
1140 + 197 (8)
1140 + 178 (10)
0.9
1260 + 101 (11)
0.08
Plasma TG (mg/dL)
Plasma HDL (mg/dL)
51 + 23 (8)
27 + 6.3 (8)
37 + 13 (10)
27 + 5.0 (10)
0.1
0.9
34 + 16 (11)
18 + 5.2 (11)
0.6
0.001
Plasma non-HDL-cholesterol (mg/dL)
1110 + 199 (8)
1120 + 177 (10)
0.9
1240 + 102 (11)
0.06
Values are mean + SD or median (25–75%) range. P values are from unpaired t test or Mann–Whitney rank-sum test. P values in right column compare SR-uPA1/0 + mU1 and SR-uPA0/0 +
PBS.
n ¼ number of mice in each group.
There was no significant effect of any of the XL784 doses on total aortic
surface area, percent aortic surface Sudan IV-positivity, or number of individual lesions on pinned aortas (P ≥ 0.4; Table 2).
3.5 Neither mU1 nor XL784 alters
peripheral blood monocyte counts or plasma
cholesterol levels in SR-uPA mice; XL784
decreases plasma triglycerides
Compared with SR-uPA mice injected with anti-TNP, injection of mU1
did not affect either total peripheral blood monocyte counts or percentages of circulating monocytes (P ≥ 0.2; Table 1). Similarly, mU1 treatment did not significantly affect plasma cholesterol, HDL-cholesterol,
non-HDL-cholesterol, or triglycerides (P ¼ 0.9 vs. anti-TNP-treated
mice for all cholesterol measurements; P ¼ 0.1 for triglycerides;
Table 1). HDL-cholesterol was increased in both groups of SR-uPA
mice vs. non-transgenic PBS-injected mice. Compared with vehicletreated mice, none of the three doses of XL784 significantly affected
either total peripheral blood monocyte counts, percentages of circulating
monocytes, total plasma cholesterol, HDL-cholesterol, or non-HDLcholesterol (P ≥ 0.2; Table 2). All three doses of XL784 significantly
decreased plasma triglycerides (50–60%; P ¼ 0.001 by ANOVA).
3.6 MMP-13 activity is significantly increased
in aortas of SR-uPA mice and correlates with
total MMP activity
Decreased atherosclerosis in SR-uPA mice treated with XL784 suggests
that uPA might accelerate atherosclerosis—at least in part—via MMP activation. A role for MMPs in uPA-accelerated atherosclerosis was
suggested by our finding of elevated total MMP activity in aorticconditioned media (CM) of SR-uPA vs. non-transgenic Apoe 2/2
mice.11 We used the inhibitory profile of XL7848 to guide experiments
aimed at identifying specific MMP(s) that are activated in aortas of
SR-uPA mice. Four MMPs are inhibited by XL784 with IC50 values in
the low nanomolar range: MMP-2 (0.81 nM), MMP-8 (10.8 nM),
MMP-9 (18 nM) and MMP-13 (0.56 nM).8 Of these, MMP-9 and
MMP-13 are activated ex vivo by Apoe 2/2 macrophages,23 making
them more likely candidates. However, our previous data provided no
support for activation of MMP-9 (or MMP-2) in aortas of SR-uPA
mice.11 Therefore, we focused our attention on MMP-8 and MMP-13.
We found no increase in MMP-8 activity in aortic CM from SR-uPA
mice (Supplementary material online, Figure S3). In contrast, MMP-13 activity was easily detected in aortic CM from all groups of mice in the mU1
study and was significantly higher in both groups of SR-uPA mice
[anti-TNP and mU1-treated; 31 + 5.4 and 32 + 3.4 D relative fluorescent units (RFU)/min, respectively] than in PBS-treated non-transgenic
mice [25 + 5.3 D relative fluorescent units (RFU)/min; P , 0.05 vs.
both groups of SR-uPA mice]. Moreover, MMP-13 activity in aortic
CM from all three groups of mice correlated highly and significantly
with total MMP activity in the same individual samples (r 2 ¼ 0.81; P ,
10210, Figure 3A). We repeated these measurements using aortic CM
from the four groups of mice in the XL784 study and again found that
MMP-13 activity was highly and significantly correlated with total MMP
activity in the same samples (r 2 ¼ 0.81; P , 10210, Figure 3B). To prospectively test the hypothesis that overexpression of uPA increases
MMP-13 activity in aortas of SR-uPA mice (and avoid potentially confounding effects of the antibody treatments), we enrolled new groups
of SR-uPA (n ¼ 12) and non-transgenic (n ¼ 16) Apoe 2/2 mice and
measured MMP-13 activity in aortic CM generated after 15 weeks of
high-fat diet. MMP-13 activity was significantly increased in aortic CM
from SR-uPA mice [37 + 3.5 vs. 29 + 5.3 D relative fluorescence units
(RFU)/min; P , 0.001, Figure 3C].
3.7 Increased MMP-13 mRNA in aortas
of recipients of SR-uPA BM
To test whether elevated aortic MMP-13 activity was associated with
elevated expression of MMP-13 in aortas of SR-uPA mice, we measured
MMP-13 mRNA in aortic mRNA available from a previous study in which
non-transgenic Apoe2/2 mice received bone marrow transplants from
either SR-uPA Apoe2/2 or non-transgenic Apoe2/2 donors.11,14
377
Protease inhibition to treat atherosclerosis
Figure 2 The selective MMP inhibitor XL784 decreases aortic root atherosclerosis in uPA-overexpressing (SR-uPA) mice. SR-uPA mice were treated for
10 weeks with either vehicle (V) (n ¼ 9) or with XL784 at one of three doses (125, 250, or 500 mg/kg/day; n ¼ 10, 11, or 12, respectively). (A) Mean intimal
area of aortic root lesions. (B) Mean aortic root intimal lesion area staining positively for oil red O (ORO). (C ) Mean aortic root intimal lesion area staining for
the macrophage marker Mac-2. (D) The circumference of the aortic root at the level of the internal elastic lamina (IEL). Data points are individual mice; bars are
group means. Aortic root lesions in uPA-overexpressing (SR-uPA) mice treated with vehicle (E and I) or three different doses of XL784 [F and J (125 mg/kg/
day); G and K (250 mg/kg/day); and H and L (500 mg/kg/day)]. Haematoxylin and eosin stain (E–H ); oil red O stain (I–L); size bar (E) ¼ 500 mm. (A, B) P values
are from one-way ANOVA with post hoc correction; (C, D) P values are from unpaired t-test. (E–L) are representative images of 9–12 aortas per group.
Table 2 Atherosclerosis in XL784- and vehicle-treated SR-uPA mice
Vehicle (n)
XL784 (mg/kg)
.......................................................................
125 (n)
250 (n)
P
500 (n)
.......................................................................................................................................................................................
Aortic root oil red O area (% of intimal area)
15 + 4.6 (9)
12 + 3.7 (10)
13 + 3.1 (11)
12 + 4.1 (12)
0.4
Aortic root Mac-2 area (% of intimal area)
Thoracic aortic lumen surface area (mm2)
22 + 7.3 (9)
36 + 1.8 (9)
22 + 8.7 (10)
37 + 4.0 (10)
20 + 6.3 (11)
37 + 3.4 (11)
16 + 5.9 (12)
35 + 1.7 (11)
0.2
0.4
Sudanophilic lesions (% of thoracic aortic luminal surface area)
3.5 (2.9– 3.9) (9)
3.7 (2.0–4.1) (10)
3.3 (2.6–3.5) (11)
3.3 (2.0–6.7) (11)
1.0
Number of lesions on pinned thoracic aorta
16 + 3.8 (9)
17 + 4.7 (10)
18 + 5.1 (11)
17 + 4.0 (11)
0.7
Peripheral blood monocytes (per mL)
Peripheral blood monocytes (% total leukocytes)
100 + 140 (5)
2.2 + 2.2 (5)
140 + 53 (5)
4.2 + 1.3 (5)
290 + 240 (5)
4.6 + 3.6 (5)
230 + 150 (5)
4.0 + 2.6 (5)
0.3
0.5
Plasma cholesterol (mg/dL)
1360 + 213 (9)
1560 + 277 (10)
1430 + 337 (11)
1280 + 295 (12)
0.2
Plasma TG (mg/dL)
Plasma HDL (mg/dL)
51 + 22 (6)
48 + 19 (9)
25 + 8.2 (6)
53 + 23 (9)
27 + 6.7 (6)
47 + 30 (11)
19 + 6.7 (6)
53 + 36 (12)
0.001
0.9
Plasma non-HDL-cholesterol (mg/dL)
1310 + 204 (9)
1490 + 276 (9)
1390 + 334 (11)
1230 + 318 (12)
0.2
Values are mean + SD or median (25 –75%) range. Number of mice in each group is in parentheses (n). P values are from one-way ANOVA.
378
J.H. Hu et al.
and visualized the resulting fragments by SDS–PAGE and silver staining
(Figure 4D). A major fragment, at 29 kDa, was identified—based on
reference to the literature24—as a potential MMP-13 catalytic fragment.
We repeated western blotting of aortic CM, selecting samples with
either high or low MMP-13 activity (n ¼ 4 each; from SR-uPA and nontransgenic mice, respectively). These blots were exposed for longer
times, revealing a lower molecular weight fragment (Figure 4E) that
co-migrated with the 29 kDa fragment produced by APMA treatment
of human MMP-13 (data not shown). The immunoreactive 29 kDa
fragment in aortic CM therefore could be an MMP-13 catalytic fragment,
generated either by autocatalysis or cleavage by a different protease.
Supporting this hypothesis, the density of the 29 kDa band in these
eight CM samples correlated highly and significantly with fluorogenic
MMP-13 activity measured in the same samples (r 2 ¼ 0.7; P ¼ 0.006;
Figure 4F).
4. Discussion
Figure 3 Aortic MMP-13 activity correlates highly with total aortic
MMP activity in individual mice and is elevated in aortas of SR-uPA vs.
non-transgenic mice. (A) Aortas from mice in the mU1 atherosclerosis
study were placed in explant culture. Fluorogenic substrates were used
to measure both total MMP activity and MMP-13 activity in the medium
conditioned by each aorta. Data points from the three groups are
indicated by separate symbols (n ¼ 11 for Ntg + PBS; n ¼ 9 for
SR-uPA + anti-TNP; and n ¼ 8 for SR-uPA + mU1). (B) The same
measurements as in (A) were made using aortic-conditioned medium
from mice in the XL784 study. Data points from vehicle-treated mice
(n ¼ 8) or XL784-treated mice (n ¼ 26) are indicated by separate
symbols. (C) Aortas from new groups of non-transgenic (n ¼ 16)
and SR-uPA mice (n ¼ 12) were placed in explant culture and
MMP-13 activity measured in conditioned media. DRFU ¼ change in
relative fluorescence units. All data points are from individual mice;
bars are group means.
Aortic MMP-13 mRNA expression was 70% higher in recipients of
SR-uPA BM [1.7 + 0.49 vs. 1.0 + 0.51 arbitrary units (AU); P ¼ 0.02;
Figure 4A].
3.8 The level of an MMP-13 fragment
correlates with MMP-13 activity in aortic CM
Western analysis of aortic CM from SR-uPA (n ¼ 6) and non-transgenic
(n ¼ 9) mice detected only a trend towards increased 65 kDa
pro-MMP-13 in aortic CM of SR-uPA mice (1.3 + 0.36 vs. 1.0 + 0.33 arbitrary units; P ¼ 0.1; Figure 4B and C and data not shown). To begin to
investigate whether active MMP-13 might be increased in SR-uPA
aortas, we first activated recombinant human MMP-13 with APMA
We used mice with macrophage-specific overexpression of uPA and elevated aortic uPA5 and MMP11 activity (SR-uPA mice) to test whether inhibition of uPA or selected MMPs could prevent atherosclerosis. Our
major findings were: (i) systemic inhibition of uPA with a murine mAb
(mU1) significantly inhibited aortic root atherosclerosis and dilation;
(ii) oral administration of a selective MMP inhibitor (XL784) significantly
inhibited aortic root atherosclerosis; (iii) MMP-13 mRNA and activity
are up-regulated in aortas of SR-uPA mice; and (iv) increased aortic
MMP-13 activity appears largely responsible for increased total aortic
MMP activity in SR-uPA mice. These experiments provide further
proof-of-concept for systemic protease inhibition as a treatment for atherosclerosis and its complications, identify MMP activity as a likely downstream mediator of uPA/plasminogen-induced atherosclerosis, and
tentatively identify MMP-13 as a key downstream mediator of uPA/
plasminogen-induced atherosclerosis.
Our first step was to determine whether mU1 could significantly
inhibit uPA in (uPA-overexpressing) SR-uPA mice. To our surprise,
SR-uPA mice were indistinguishable from non-transgenic mice in their
susceptibility both to the uPA-activated toxin PrAg-U2/FP59 and to
rescue from PrAg-U2/FP59 toxicity by mU1. These findings support
the hypothesis that PrAg-U2/FP59 toxicity is mediated at a limited
number of cell-surface uPA binding sites rather than systemically,15
and suggest that—in SR-uPA mice—cell-surface uPA is increased far
less than total body uPA mRNA and protein. Accordingly, only a small
percentage of uPA in PrAg-U2/FP59-injected SR-uPA mice may be biologically active with the remainder in the inactive single-chain form. This
small percentage of active (cell surface) uPA appears to be inhibited by
the same dose of mU1 in both SR-uPA and non-transgenic mice. A corollary of this interpretation is that—although SR-uPA mice have dramatically increased atherosclerosis that is caused by uPA catalytic
activity5,9—they appear to have only a modestly increased level of in
vivo uPA activity, as measured by the bioassay of in vivo PrAg-U2/FP59
toxicity (the toxicity of which is clearly mediated by cell-surface uPA
activity).16
In addition to protecting against PrAg-U2/FP59 toxicity, mU1
decreased atherosclerosis and limited aortic dilation in SR-uPA mice.
This result supports a role for cell-surface uPA activity in accelerating
atherosclerosis and aneurysm formation and suggests that uPA inhibitors may be therapeutically useful. More complete inhibition of cellsurface uPA either by more potent antibodies or with small-molecule
inhibitors would likely be more effective than mU1 both in blocking
Protease inhibition to treat atherosclerosis
379
Figure 4 Expression and activity of MMP-13 mRNA and protein in aortas of SR-uPA and non-transgenic mice. (A) MMP-13 mRNA was measured by
qRT-PCR of aortic RNA of mice21 that had received bone marrow transplants from either non-transgenic (n ¼ 8 recipients) or SR-uPA donors (n ¼ 7
recipients) (AU ¼ arbitrary units). (B) Representative image of western blot of medium conditioned by aortas of either non-transgenic (n ¼ 5) or
SR-uPA mice (n ¼ 4). Bands in the upper panel were identified as pro-MMP-13 by their migration distance (65 kDa). (C) Densitometry analysis of
bands in western blot shown in (B) and in a western blot of other samples (not shown). Samples are from a total of nine non-transgenic and six SR-uPA
mice. (D) Detection of an MMP-13 fragment that may represent the catalytic domain (arrow) by gel electrophoresis and silver staining. Recombinant
MMP-13 was analysed either without (left lane) or with (right 2 lanes) pre-treatment with amino-phenyl mercuric acetate (APMA). The MMP-13 was
then loaded either without dilution (centre lane) or after 1:10 dilution. Major protein bands were identified by their migration distances, with reference
to the literature.16 (E) Western blot of medium conditioned by aortas of either SR-uPA or non-transgenic mice (n ¼ 4 for each). Pro-MMP-13 and an
MMP-13 fragment that could represent the catalytic domain (arrow) were identified by their migration distances, with reference to the literature.16 Membrane was stripped and reprobed with anti-GAPDH antibody. (F) Correlation of MMP-13 activity [D relative fluorescence units (RFU)/min] with density of
29 kDa band [arrow in (E)] on western blot of the same conditioned medium samples. Samples from SR-uPA and non-transgenic mice are indicated.
AU ¼ arbitrary units. (A – C; E, F) Each lane or point represents one mouse; bars (A, C) are group means. Size markers (D, E) and are in kDa.
PrAg-U2/FP59 toxicity and in preventing vascular pathology. When
these more potent inhibitors are available, they could be tested first in
the present model and then in other mouse models, including
atherosclerosis-prone mice that do not overexpress uPA and bone
marrow-chimeric SR-uPA mice that exhibit increased plaque rupture.11
XL784 also inhibited atherosclerosis, with a trend towards less aortic
dilation at all doses. Data from transgenic and knockout mice show that
individual MMPs can both prevent and accelerate atherosclerosis.7,12
Accordingly, broad-spectrum MMP inhibitors have not reduced atherosclerosis in animal models,7,12,25 and the effect on atherosclerosis of a
limited-spectrum MMP inhibitor such as XL784 was not predictable.
Other, more specific MMP inhibitors have shown promise in mice, including an MMP-12 inhibitor that reduced plaque size26 and an
MMP-13 inhibitor that increased plaque collagen content (with no
380
effect on lesion size).19 Our study is the first to show that a semi-selective
MMP inhibitor can retard atherosclerosis. Moreover, the trend towards
smaller aortic diameter in XL784-treated mice is consistent with a
recent study, showing that XL784 was protective in a mouse model of
elastase-induced aortic aneurysm.18 The larger effect of XL784 in this
other study may be due to the more severe aortic damage in elastasetreated vs. uPA-overexpressing mice. Interestingly, in the present
study XL784 was marginally more effective at the lowest dose (by
t-test the decrease in aortic diameter of mice treated with XL784 at
125 mg/kg was statistically significant; P ¼ 0.04). Lack of dose–response
effects of XL784 might be due to saturation of MMP active sites at the
lowest XL784 dose or inhibition of protective MMPs at higher XL784
doses. Overall, the XL784 results suggest that MMP activity may be a
downstream mediator of uPA-induced atherosclerosis and identify
XL784—which is well tolerated so far in humans27,28—as a clinically
promising MMP inhibitor.
Our experiments do not identify the mechanisms through which mU1
and XL784 retard atherosclerosis, but presumably they do so by inhibiting atherogenic proteolytic activities of uPA and MMPs. These activities
could include enhancement of foam cell formation,29 activation of
growth factors,30 and stimulation of pro-inflammatory pathways.14,31
We are confident that mU1 blocks uPA proteolytic activity in vivo
because it delays PrAg-U2 toxicity, which is mediated by uPA catalytic
activity. In vivo blockade of MMP activity by XL784 is less easily confirmed. For example, we did not find a significant decrease in total
MMP activity in aortic CM from XL784-treated vs. vehicle-treated
mice (data are in Figure 3B), which we attribute to washout of XL784
during aortic harvest and culture while aortic secretion of uPA and
MMPs persists. Similarly, aortic MMP activity was not reduced in
explant cultures of mU1-treated vs. anti-TNP-treated mice (data are
in Figure 3A). However, inhibition of MMP activity in XL784-treated
mice is supported by the finding of significant hypotriglyceridemia in
all XL784-treated groups. This finding mirrors hypotriglyceridemia in
mice and rats treated with other MMP inhibitors32,33 and is therefore
a likely indicator of biologically significant MMP inhibition in
XL784-treated mice. Hypotriglyceridemia could theoretically contribute to atheroprotective effects of XL784. However, we feel that this
is unlikely based on the data from both humans and mice, showing
that variability in triglycerides alone does not affect the extent of
atherosclerosis.34 – 37 Moreover, there is an overwhelming abundance
of plasma cholesterol vs. triglycerides in Apoe 2/2 mice and XL784 had
no effect on plasma cholesterol.
The plasma lipid analyses also yielded an unanticipated and potentially
important result: both groups of SR-uPA mice had significantly increased
plasma HDL-cholesterol (50% increase above levels in non-transgenic
mice). Two other groups reported significantly lower plasma HDL in
plasminogen-null Apoe 2/2 mice.29,38 In both of these studies, the decrease in plasma HDL associated with the absence of plasminogen is
large: 45 –67%. These data, along with the data in the present manuscript, suggest that plasmin activity (increased in SR-uPA mice; decreased
in plasminogen-null mice) may be a major regulator of plasma HDL
levels, at least in Apoe 2/2 mice. Potential mechanisms could include
effects on HDL biogenesis, uptake, or cholesterol transfer among
plasma lipoproteins. Prospective studies in normolipidemic as well as
hyperlipidaemic mice are needed to further define the relationship
between plasmin(ogen) and HDL.
Because both mU1 and XL784 suppress aortic root lesion growth
without affecting more distal aortic atherosclerosis (neither aortic
surface coverage nor number of aortic surface lesions were decreased),
J.H. Hu et al.
mU1 and XL784 appear to block lesion progression (i.e. addition of
lipid, macrophages, and matrix to established lesions) rather than lesion
initiation (entry of lipid and monocytes to normal arterial tissue). This is
congruent with previous results that support a role for uPA in lesion progression rather than initiation.14,21 Consistent with this interpretation,
neither mU1 nor XL784 lowered circulating monocyte numbers.
Rather, both agents increased circulating monocyte counts, although
not significantly. Nevertheless, because of the small number of measurements and the variability of circulating monocyte values, we cannot confidently exclude significant decreases.
We used a substrate-screening approach, guided by the inhibitory
profile of XL784,8 to identify which MMP is responsible for increased
total MMP activity in SR-uPA aortas. Several lines of evidence implicate
MMP-13: (i) MMP-13 mRNA is up-regulated in aortas of SR-uPA mice;
(ii) the magnitude of elevated MMP-13 activity in SR-uPA aortic CM
(30%) is identical to the magnitude of elevated total MMP activity in
SR-uPA aortic CM11; and (iii) total MMP activity and MMP-13 activity
in individual aortic CM samples are highly correlated. Moreover,
others have shown that MMP-13 is present in atherosclerotic mouse
aorta and is activated (in vitro) by uPA-generated plasmin.23,39
We also found a 30% increase in pro-MMP-13 protein in SR-uPA vs.
non-transgenic aortic CM. This increase—while not statistically significant—is essentially identical to the 27% increase in MMP-13 activity in
aortic CM of SR-uPA mice. Lack of statistical significance of the increase
in pro-MMP-13 protein could be due to the semi-quantitative nature of
western blotting, compared with the more precisely quantitative assays
used to measure MMP-13 mRNA (qRT-PCR) and MMP-13 activity
(a fluorogenic assay). Our finding of a high correlation between the
abundance of a possible MMP-13 catalytic fragment (also found by
others in vivo)40 and the level of MMP-13 activity in the same aortic
CM samples also supports a conclusion that MMP-13 is the mediator
of increased total MMP activity in SR-uPA mice. Nevertheless, extensive
efforts that we made to generate further support for this conclusion
were unsuccessful. These included: the use of an MMP-13 antibody to
remove MMP activity from aortic CM by immunoprecipitation (this
was successful but so were control immunoprecipitations); elution of
proteins immunoprecipitated from aortic CM by the MMP-13 antibody
used for western blotting and identification of the proteins by mass spectrometry (no MMP-13 fragments were identified; possibly because the
antibody recognizes denatured but not native mouse MMP-13); and
treatment of aortic CM with a proprietary MMP-13 inhibitor19 (it did
not suppress total MMP activity). The possibility that the MMP-13 substrate detects other activities must be considered. However, the most
probable candidates for cleaving this type of substrate [the collagenases
MMP-8 and MMP-141,42 (see also manufacturer’s product sheet)] are
unlikely because we found no activity with an MMP-8 substrate and
mice do not have MMP-1. More definitive evidence of a biological role
for MMP-13 as a downstream mediator of uPA-stimulated proteolysis,
total MMP activity, and vascular pathology awaits further experimentation, possibly in MMP-13-null mice. We are aware of reports that deletion of MMP-13 does not reduce mouse atherosclerosis.43,44 However,
as with uPA,5,11,23 increased expression of MMP-13 may affect atherosclerosis more profoundly than MMP-13 deletion.
Another question for the future is why—among all MMPs that are
present in atherosclerotic aortas—uPA activates only MMP-13. Quillard
et al. also found that MMP-13 is preferentially activated in mouse aorta, at
least in comparison with MMP-8.44 We speculate that preferential activation of MMP-13 in aortas of SR-uPA mice could be because MMP-13
can be directly activated by plasmin, because MMP-13 may have a lower
Protease inhibition to treat atherosclerosis
affinity for vascular MMP inhibitors, or because selective extracellular localization of MMP-13 may facilitate its association with uPA and plasmin.
Interaction of the uPA receptor and MMP-1345 supports the notion of
selective extracellular localization of MMP-13 that could lead to preferential activation by uPA/plasminogen.
In summary, a specific antibody directed at murine uPA and a smallmolecule selective MMP inhibitor both suppress atherosclerosis in
SR-uPA mice. Direct uPA inhibition also suppresses aortic dilation.
These results (obtained in a model in which atherosclerosis and aortic
dilation are clearly protease-driven) support a role for uPA in both
atherogenesis and aneurysm formation. Future studies will test these
interventions in other animal models, including those without protease
overexpression and in animal models of protease-driven plaque
rupture.11 Efficacy in these settings would further support our hypothesis that mU1, XL784, or related protease inhibitors have promise for
translation into human cardiovascular therapeutics.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
Acknowledgements
Symphony Capital kindly provided XL784 for use in this study, which was
conceived, designed, executed, analyzed, and prepared for publication
solely by the academic investigators. Symphony provided no financial
support to the laboratory or the investigators in any form. Amgen
kindly provided the MMP-13 inhibitor.
Conflict of interest: D.A.D. and J.H.H. are co-inventors on a patent
application for use of XL784 for treatment of atherosclerosis. S.L. was
supported by the intramural research program of the National Institute
of Allergy and Infectious Diseases, National Institutes of Health.
Funding
This study was supported by grants from the John L. Locke Jr. Charitable
Trust and from the National Heart, Lung and Blood Institute
(R21HL113405). The content is solely the responsibility of the authors
and does not necessarily represent the official views of the National
Heart, Lung, and Blood Institute or the National Institutes of Health.
References
1. Garcia-Touchard A, Henry TD, Sangiorgi G, Spagnoli LG, Mauriello A, Conover C,
Schwartz RS. Extracellular proteases in atherosclerosis and restenosis. Arterioscler
Thromb Vasc Biol 2005;25:1119 –1127.
2. Simon DI, Jain MK. Targeting proteases in atherosclerosis: hitting the nail with the
hammer. Circulation 2011;124:2480 –2482.
3. Dollery CM, Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res 2006;69:
625 –635.
4. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov
2006;5:785 –799.
5. Cozen AE, Moriwaki H, Kremen M, DeYoung MB, Dichek HL, Slezicki KI, Young SG,
Veniant M, Dichek DA. Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death. Circulation
2004;109:2129 –2135.
6. Fuhrman B. The urokinase system in the pathogenesis of atherosclerosis. Atherosclerosis
2012;222:8 –14.
7. Janssens S, Lijnen HR. What has been learned about the cardiovascular effects of matrix
metalloproteinases from mouse models? Cardiovasc Res 2006;69:585 – 594.
8. Williams JM, Zhang J, North P, Lacy S, Yakes M, Dahly-Vernon A, Roman RJ. Evaluation of
metalloprotease inhibitors on hypertension and diabetic nephropathy. Am J Physiol Renal
Physiol 2011;300:F983 – F998.
9. Kremen M, Krishnan R, Emery I, Hu JH, Slezicki K, Wu A, Qian K, Du L, Plawman A,
Stempien-Otero A, Dichek DA. Plasminogen mediates the atherogenic effects of
macrophage-expressed urokinase and accelerates atherosclerosis in apoe-knockout
mice. Proc Natl Acad Sci USA 2008;105:17109 –17114.
381
10. Plow EF, Hoover-Plow J. The functions of plasminogen in cardiovascular disease. Trends
Cardiovasc Med 2004;14:180 –186.
11. Hu JH, Du L, Chu T, Otsuka G, Dronadula N, Jaffe M, Gill SE, Parks WC, Dichek DA.
Overexpression of urokinase by plaque macrophages causes histologic features of
plaque rupture and increases vascular mmp activity in aged apo e-null mice. Circulation
2010;121:1637 –1644.
12. Newby AC. Matrix metalloproteinase inhibition therapy for vascular diseases. Vascul
Pharmacol 2012;56:232–244.
13. Lund IK, Jogi A, Rono B, Rasch MG, Lund LR, Almholt K, Gardsvoll H, Behrendt N,
Romer J, Hoyer-Hansen G. Antibody-mediated targeting of the urokinase-type plasminogen activator proteolytic function neutralizes fibrinolysis in vivo. J Biol Chem
2008;283:32506 –32515.
14. Farris SD, Hu JH, Krishnan R, Emery I, Chu T, Du L, Kremen M, Dichek HL, Gold E,
Ramsey SA, Dichek DA. Mechanisms of urokinase plasminogen activator (UPA)mediated atherosclerosis: role of the upa receptor and s100a8/a9 proteins. J Biol Chem
2011;286:22665 –22677.
15. Liu S, Bugge TH, Leppla SH. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem 2001;276:17976 –17984.
16. Liu S, Aaronson H, Mitola DJ, Leppla SH, Bugge TH. Potent antitumor activity of a
urokinase-activated engineered anthrax toxin. Proc Natl Acad Sci USA 2003;100:
657 –662.
17. Lund IK, Rasch MG, Ingvarsen S, Pass J, Madsen DH, Engelholm LH, Behrendt N,
Hoyer-Hansen G. Inhibitory monoclonal antibodies against mouse proteases raised in
gene-deficient mice block proteolytic functions in vivo. Front Pharmacol 2012;3:122.
18. Ennis T, Jin J, Bartlett S, Arif B, Grapperhaus K, Curci JA. Effect of novel limited-spectrum
mmp inhibitor xl784 in abdominal aortic aneurysms. J Cardiovasc Pharmacol Ther 2012;17:
417 –426.
19. Quillard T, Tesmenitsky Y, Croce K, Travers R, Shvartz E, Koskinas KC, Sukhova GK,
Aikawa E, Aikawa M, Libby P. Selective inhibition of matrix metalloproteinase-13
increases collagen content of established mouse atherosclerosis. Arterioscler Thromb
Vasc Biol 2011;31:2464 –2472.
20. Golovchenko S, Hattori T, Hartmann C, Gebhardt M, Gebhard S, Hess A, Pausch F,
Schlund B, von der Mark K. Deletion of beta catenin in hypertrophic growth plate chondrocytes impairs trabecular bone formation. Bone 2013;55:102 –112.
21. Krishnan R, Kremen M, Hu JH, Emery I, Farris SD, Slezicki KI, Chu T, Du L, Dichek HL,
Dichek DA. Level of macrophage upa expression is an important determinant of atherosclerotic lesion growth in apoe-/- mice. Arterioscler Thromb Vasc Biol 2009;29:1737 –1744.
22. Rono B, Romer J, Liu S, Bugge TH, Leppla SH, Kristjansen PE. Antitumor efficacy of a urokinase activation-dependent anthrax toxin. Mol Cancer Ther 2006;5:89 –96.
23. Carmeliet P, Moons L, Lijnen R, Baes M, Lemaitre V, Tipping P, Drew A, Eeckhout Y,
Shapiro S, Lupu F, Collen D. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997;17:439 –444.
24. Knauper V, Cowell S, Smith B, Lopez-Otin C, O’Shea M, Morris H, Zardi L, Murphy G.
The role of the c-terminal domain of human collagenase-3 (mmp-13) in the activation
of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem 1997;272:7608 –7616.
25. Johnson JL, Fritsche-Danielson R, Behrendt M, Westin-Eriksson A, Wennbo H,
Herslof M, Elebring M, George SJ, McPheat WL, Jackson CL. Effect of broad-spectrum
matrix metalloproteinase inhibition on atherosclerotic plaque stability. Cardiovasc Res
2006;71:586 –595.
26. Johnson JL, Devel L, Czarny B, George SJ, Jackson CL, Rogakos V, Beau F, Yiotakis A,
Newby AC, Dive V. A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein e-knockout mice. Arterioscler Thromb
Vasc Biol 2011;31:528 – 535.
27. Arribas J, Esselens C. Adam17 as a therapeutic target in multiple diseases. Curr Pharm Des
2009;15:2319 –2335.
28. Abboud H, Liljenquist J, Blumenthal S, Ervin W, Rendell M, Aggarwal SK, Mitchell B,
Wiliams M. Effect of protease inhibition by xl784 in patients with diabetic nephropathy.
J. Am. Soc. Nephrol. 2007;18:329A (abstract).
29. Das R, Ganapathy S, Mahabeleshwar GH, Drumm C, Febbraio M, Jain MK, Plow EF.
Macrophage gene expression and foam cell formation are regulated by plasminogen. Circulation 2013;127:1209 – 1218.
30. Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor b1 by plasmin. J Cell Biol 1990;110:1361 –1367.
31. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino
Acids 2011;41:271–290.
32. Van Hul M, Bauters D, Lijnen RH. Differential effects of a gelatinase inhibitor on adipocyte differentiation and adipose tissue development. Clin Exp Pharmacol Physiol 2013;40:
689 –697.
33. Morikawa T, Toyama T, Kudo N, Kawashima Y. Reducing effect of matrix metalloproteinase inhibitors on serum triacylglycerol in streptozotocin-induced diabetic rats and
zucker fa/fa rats. Biol Pharm Bull 2007;30:1461 –1467.
34. Goldberg IJ, Eckel RH, McPherson R. Triglycerides and heart disease: still a hypothesis?
Arterioscler. Thromb Vasc Biol 2011;31:1716 –1725.
35. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM,
Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993 –2000.
382
36. Semenkovich CF, Coleman T, Daugherty A. Effects of heterozygous lipoprotein lipase
deficiency on diet-induced atherosclerosis in mice. J Lipid Res 1998;39:1141 –1151.
37. Calleja L, Paris MA, Paul A, Vilella E, Joven J, Jimenez A, Beltran G, Uceda M, Maeda N,
Osada J. Low-cholesterol and high-fat diets reduce atherosclerotic lesion development
in apoe-knockout mice. Arterioscler Thromb Vasc Biol 1999;19:2368 –2375.
38. Xiao Q, Danton MJS, Witte DP, Kowala MC, Valentine MT, Bugge TH, Degen JL. Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Proc Natl Acad Sci USA 1997;94:10335 –10340.
39. Netzel-Arnett S, Mitola DJ, Yamada SS, Chrysovergis K, Holmbeck K, BirkedalHansen H, Bugge TH. Collagen dissolution by keratinocytes requires cell surface plasminogen activation and matrix metalloproteinase activity. J Biol Chem 2002;277:
45154 –45161.
40. Nakamura H, Sato G, Hirata A, Yamamoto T. Immunolocalization of matrix
metalloproteinase-13 on bone surface under osteoclasts in rat tibia. Bone 2004;34:
48 –56.
J.H. Hu et al.
41. Knight CG, Willenbrock F, Murphy G. A novel coumarin-labelled peptide for sensitive
continuous assays of the matrix metalloproteinases. FEBS Lett 1992;296:263–266.
42. Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G. Biochemical characterization of
human collagenase-3. J Biol Chem 1996;271:1544 –1550.
43. Deguchi JO, Aikawa E, Libby P, Vachon JR, Inada M, Krane SM, Whittaker P, Aikawa M.
Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation
and organization in mouse atherosclerotic plaques. Circulation 2005;112:2708 –2715.
44. Quillard T, Araujo HA, Franck G, Tesmenitsky Y, Libby P. Matrix metalloproteinase-13
predominates over matrix metalloproteinase-8 as the functional interstitial collagenase
in mouse atheromata. Arterioscler Thromb Vasc Biol 2014;34:1179 –1186.
45. Engelholm LH, Nielsen BS, Netzel-Arnett S, Solberg H, Chen XD, Lopez Garcia JM,
Lopez-Otin C, Young MF, Birkedal-Hansen H, Dano K, Lund LR, Behrendt N,
Bugge TH. The urokinase plasminogen activator receptor-associated protein/endo180
is coexpressed with its interaction partners urokinase plasminogen activator receptor
and matrix metalloprotease-13 during osteogenesis. Lab Invest 2001;81:1403–1414.